BFRI — Biofrontera Inc.

Summary of Biofrontera Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $17.1 million, up 36% year-over-year, marking the highest quarterly revenue in company history.
• Full Year 2025 Revenue: $41.7 million, a 12% increase from $37.3 million in 2024.
• Adjusted EBITDA: Q4 adjusted EBITDA was $4.9 million, compared to a negative $1.4 million in Q4 2024. Full-year adjusted EBITDA improved to negative $10.6 million from negative $15.3 million in 2024.
• Net Income: Q4 net income reached $5.6 million, a significant turnaround from a net loss of $1.4 million in Q4 2024. Full-year net loss was reduced to $10.5 million from $17.8 million in 2024.
• Gross Profit Margin: Improved to 82% in Q4 2025, up from 58% in Q4 2024, driven by a new earn-out structure with lower costs.

2. Strategic Updates and Business Highlights

• Acquisition of U.S. Rights: Biofrontera completed a significant transaction with Biofrontera AG, acquiring all U.S. rights, approvals, and patents for Ameluz and RhodoLED, enhancing control over its product offerings.
• Regulatory Milestones: The FDA accepted a supplemental NDA for Ameluz in treating superficial basal cell carcinoma (sBCC), with a PDUFA target action date of September 28, 2026.
• Clinical Progress: Positive Phase III results for actinic keratosis (AK) on extremities and promising Phase II results for moderate to severe acne vulgaris were reported.
• Sales Growth: Ameluz unit volumes increased by 10% year-over-year, with approximately 121,000 tubes sold in 2025.

3. Forward Guidance and Outlook

• Gross Margin Expectations: Management anticipates gross profit margins to stabilize between 80% and 85% throughout 2026, with the full benefit of the new cost structure expected to materialize.
• Continued Growth: The company aims to leverage its expanded clinical pipeline and improved commercial strategy to drive further revenue growth and approach cash flow breakeven.

4. Bad News, Challenges, or Points of Concern

• Legal Expenses: Increased legal costs related to patent claims have contributed to rising operating expenses, with SG&A expenses up by 12% in 2025.
• Net Loss: Although significantly improved, the company still reported a net loss for the year, indicating ongoing financial challenges.
• Patent Disputes: While a favorable ruling was received against Sun Pharma, the potential for further review poses ongoing risks.

5. Notable Q&A Insights

• Gross Margin Variability: In response to a question about gross margin fluctuations, management indicated that margins would likely start at around 82% and could vary based on product mix throughout the year.
• Future Sales Strategy: The success of an inside sales pilot in Q4 2025 is prompting plans for a full rollout in 2026, aimed at expanding market reach.

Overall, Biofrontera Inc. demonstrated strong financial performance in Q4 2025, driven by strategic acquisitions and clinical advancements, while also addressing ongoing challenges related to legal expenses and net losses. The outlook for 2026 appears positive, with expectations for improved margins and continued growth.